Nathan Dolloff to Bortezomib
This is a "connection" page, showing publications Nathan Dolloff has written about Bortezomib.
Connection Strength
1.159
-
Tuning isoform selectivity and bortezomib sensitivity with a new class of alkenyl indene PDI inhibitor. Eur J Med Chem. 2020 Jan 15; 186:111906.
Score: 0.646
-
Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo. Leuk Res. 2020 01; 88:106271.
Score: 0.161
-
Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance. Adv Cancer Res. 2015; 127:191-226.
Score: 0.117
-
High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma. Leukemia. 2014 Nov; 28(11):2263-7.
Score: 0.111
-
Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9. Mol Cancer Ther. 2012 Nov; 11(11):2321-30.
Score: 0.098
-
Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. Mol Cancer Ther. 2013 Jun; 12(6):1140-50.
Score: 0.025